Opiates and Prescription Drugs



There has been a dramatic change in the opiate abuse problem in the United States during the last decade. Opiate pharmaceuticals have replaced heroin as the dominant drugs of abuse, and the number of users has quadrupled. In both 2005 and 2006, pain relievers replaced marijuana as the most common new drug of abuse among first-time users aged 12 and older. The number of individuals meeting criteria for opiate use disorders has almost tripled and now approaches 2 million adults and adolescents. There has also been a shift in demographics, with new users more likely to be White, employed, and better educated. Compared with heroin abusers, this group is less sociopathic, but more likely to have had prior treatment for other psychiatric disorders. Fortunately, the treatment options for these individuals are also more diverse and accessible. Traditionally, long-term therapeutic communities and methadone maintenance programs offered the only effective treatment for most opiate addicts. With the Food and Drug Administration’s approval of buprenorphine for use in office-based settings, a new and highly effective treatment has become available and has gained wide acceptance among clients. The most effective treatments approach opiate dependence as a chronic, relapsing disease that requires long-term care and that integrates comprehensive medical and psychiatric services to address co-occurring conditions.


Behavioral couples therapy Buprenorphine Cognitive behavior therapy Contingency management Detoxification Drug Addiction Treatment Act of 2000 Drug courts Epidemiology Etiology Iatrogenic addiction Levo-alpha acetyl methadol Methadone Methadone maintenance Motivational enhancement therapy Naloxone Naltrexone Neurobiology Office-based treatment Opioid overdose Opioid receptors OxyContin® Partial opioid agonist Primary prevention Psychiatric comorbidity Psychosocial treatment Substance-induced disorders Therapeutic communities Tolerance Twelve-step facilitation Withdrawal 


  1. 1.
    Abbott PJ, Weller SB, Delaney HD et al (1998) Community reinforcement approach in the treatment of opiate addicts. Am J Drug Alcohol Abuse 24:17–30PubMedGoogle Scholar
  2. 2.
    Amato L, Minozzi S, Davoli M et al (2004) Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 18(4):CD004147Google Scholar
  3. 3.
    American Academy of Pain Medicine, American Pain Society, American Society of Addiction Medicine (2004) Public policy statement on the rights and responsibilities of healthcare professionals in the use of opioids for the treatment of pain. http://www.ampainsoc.org/advocacy/rights.htm accessed 31 May 2010
  4. 4.
    American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders. 4th edn, text revision. American Psychiatric Publishing, Washington, DCGoogle Scholar
  5. 5.
    Anthony JC, Warner LA, Kessler RC (1994) Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalents: basic findings from the national comorbidity survey. Exp Clin Psychopharmacol 3:224–268Google Scholar
  6. 6.
    Assadi SM, Radgoodarzi R, Ahmed-Abhari SA (2003) Baclofen for maintenance treatment of opioid dependence: a randomized double-blind placebo-controlled clinical trial. BMC Psychiatry 18(3):16Google Scholar
  7. 7.
    Ball J, Ross A (1991) The effectiveness of methadone maintenance treatment. Springer, New YorkGoogle Scholar
  8. 8.
    Bart G, Borg L, Schluger JH et al (2003) Suppressed prolactin response to dynorphin A1–13 in methadone-maintained versus control subjects. Pharmacol Exp Ther 306(2):581–587Google Scholar
  9. 9.
    Bickel WK, Amass L, Higgins ST et al (1997) Effects of adding behavioral treatment to opioid detoxification with buprenorphine. J Consult Clin Psychol 65:803–810PubMedGoogle Scholar
  10. 10.
    Bleich A, Gelkopf M, Weizman T, et al (2002) Benzodiazepine abuse in a methadone maintenance treatment clinic in Israel: characteristics and a pharmacotherapeutic approach. Isl J Psychiatry Relat Sci 39:104–112Google Scholar
  11. 11.
    Borron SW, Monier C, Risede P, et al (2002) Funitrazepam variably alters morphine, buprenorphine, and methadone lethality in the rat. Hum Exp Toxicol 21:599–605PubMedGoogle Scholar
  12. 12.
    Boyd J, Randell T, Luurila H, Kuisma M (2003) Serious overdoses involving buprenorphine in Helsinki. Acta Anaesthesiol Scand 47:1031–1033PubMedGoogle Scholar
  13. 13.
    Brands B, Blake J, Sproule B, et al (2004) Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend 73:199–207PubMedGoogle Scholar
  14. 14.
    Brewer C (1997) Ultra-rapid antagonist-precipitated opiate detoxification under general anaesthesia or sedation. Addict Biol 2:291–302Google Scholar
  15. 15.
    Brook DW (2008) Group therapy. In: Galanter M, Kleber HD (eds) Textbook of substance abuse treatment, 4th edn. American Psychiatric Publishing, Washington, DCGoogle Scholar
  16. 16.
    Brooner RK, Bigelow GE, Regier MW (1989) Methadone maintenance: high rate of other substance use disorders and relationship to psychiatric comorbidity. NIDA Res Monogr 95:442PubMedGoogle Scholar
  17. 17.
    Brooner RK, King VL, Kidorf M et al (1997) Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Arch Gen Psychiatry 54(1):71–80PubMedGoogle Scholar
  18. 18.
    Brunette MF, Mueser KT (2006) Psychosocial interventions for the long-term management of patients with severe mental illness and co-occurring substance use disorders. J Clin Psychiatry 67(Suppl 7):10–17PubMedGoogle Scholar
  19. 19.
    Buydens-Branchey L, Branchey M, Reel-Brander C (2005) Efficacy of buspirone in the treatment of opioid withdrawal. J Clin Psychopharmacol 25:230–236PubMedGoogle Scholar
  20. 20.
    Calsyn DA, Malcy JA, Saxon AJ (2006) Slow tapering from methadone maintenance in a program encouraging indefinite maintenance. J Subst Abuse Treat 30:159–163PubMedGoogle Scholar
  21. 21.
    Carpenter KM, Brooks AC, Vosburg SK et al (2004) The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: a controlled clinical trial. Drug Alcohol Depend 74:123–134PubMedGoogle Scholar
  22. 22.
    Carroll KM (2008) Cognitive-behavioral therapies. In: Galanter M, Kleber HD (eds) Textbook of substance abuse treatment, 4th edn. American Psychiatric Publishing, Washington, DCGoogle Scholar
  23. 23.
    Carroll KM, Ball SA, Nich C et al (2001) Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry 58:755–761PubMedGoogle Scholar
  24. 24.
    Carroll KM, Sinha R, Nich C et al (2002) Contingency management to enhance naltrexone treatment of opioid dependence: a randomized clinical trial of reinforcement. Exper Clin Psychopharmacol 10:54–63Google Scholar
  25. 25.
    Chen Y, Mestek A, Liu J, et al (1993) Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol 44:8–12PubMedGoogle Scholar
  26. 26.
    Chen Y, Mestek A, Liu J, et al (1993) Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to mu and delta opioid receptors. Biochem J 295:625–628PubMedGoogle Scholar
  27. 27.
    Comer SD, Sullivan MA, Yu E et al (2006) Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 63:210–218PubMedGoogle Scholar
  28. 28.
    Compton WM, Thomas YF, Stinson FS et al (2007) Prevalence, correlates, disability, and comorbiduty of DSM-IV drug abuse and dependence in the United States. Results from the national epidmeiologic survey on alcohol and related conditions. Arch Gen Psychiatry 64:566–576PubMedGoogle Scholar
  29. 29.
    Compton WM, Denisco R (2008) Prescription drug abuse. In: Galanter M, Kleber HD (eds) Textbook of substance abuse treatment, 4th edn. American Psychiatric Publishing, Washington, DCGoogle Scholar
  30. 30.
    Corbett AD, Henderson G, McKnight AT et al (2006) 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol 147(Suppl 1):S153–S162PubMedGoogle Scholar
  31. 31.
    Cowan A (2007) Buprenorphine: the basic pharmacology revisited. J Addict Med 1:68–72PubMedGoogle Scholar
  32. 32.
    DeLeon G (2008) Therapeutic communities. In: Glanater M, Kleber HD (eds) Textbook of substance abuse treatment, 4th edn. American Psychiatric Publishing, Washington, DCGoogle Scholar
  33. 33.
    Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Results from the 2006 National Survey on Drug Use and Health. http://oas.samhsa.gov/NSDUH/2k6NSHDUH/2k6results.cfm#Ch5. Accessed 29 June 2008
  34. 34.
    Deykin EY, Buka SL (1997) Prevalance and risk factors for posttraumatic stress disorder among chemically dependent adolescents. Am J Psychiatry 154(6):752–757PubMedGoogle Scholar
  35. 35.
    DiClemente CC, Garay M, Gemmell L (2008) Motivational enhancement. In: Galanter M, Kleber HD (eds) Textbook of substance abuse treatment, 4th edn. American Psychiatric Publishing, Washington, DCGoogle Scholar
  36. 36.
    Dobler-Mikola A, Hattenschwiler J, Meili D et al (2005) Patterns of heroin, cocaine, and alcohol abuse during long-term methadone maintenance treatment. J Subst Abuse Treat 29(4):259–265PubMedGoogle Scholar
  37. 37.
    Dole VP, Nyswander M (1965) A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA 193:646–650Google Scholar
  38. 38.
    Dutra L, Stathopoulou G, Basden SL et al (2008) A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 165:179–187PubMedGoogle Scholar
  39. 39.
    Evans CJ, Keith DE Jr, Morrison H et al (1992) Cloning of a delta-opioid receptor by functional expression. Science 258:1952–1955PubMedGoogle Scholar
  40. 40.
    Fiellin DA (2006) Buprenorphine: effective treatment of opioid addiction starts in the office. Am Fam Physician 73:1513–1514PubMedGoogle Scholar
  41. 41.
    Fiellin DA, Pantalon MV, Chawarski MC et al (2006) Counseling plus buprenorphine–naloxone maintenance therapy for opioid dependence. N Eng J Med 355(4):365–374Google Scholar
  42. 42.
    Finley MJ, Happel CM, Kaminsky DE et al (2008) Opioid and nocicpetin receptors regulate cytokine and cytokine receptor expression. Cell Imunol 252(1–2):146–154Google Scholar
  43. 43.
    Flores PJ (2004) Addiction as an attachment disorder. Jason Aronson, Lanham, MDGoogle Scholar
  44. 44.
    Gelernter J, Panhuysen C, Wilcox M et al (2006) Genomewide linkage scan for opioid dependence and related traits. Am J Hum Genet 78(5):759–769PubMedGoogle Scholar
  45. 45.
    Gowing L, Ali R, White J (2006) Buprenorphine for the management of opioid withdrawal (Cochrane review). Cochrane Database Syst Rev 2:CD002025PubMedGoogle Scholar
  46. 46.
    Gowing L, Ali R, White J (2006) Opioid antagonists with minimal sedation for opioid withdrawal (Cochrane review). Cochrane Database Syst Rev 1:CD002021PubMedGoogle Scholar
  47. 47.
    Grant BF (1996) Prevalence and correlates of drug use and DSM-IV drug dependence in the United States: results from the National Longitudinal Alcohol Epidemiologic Survey. J Subst Abuse 8:195–21PubMedGoogle Scholar
  48. 48.
    Green AI, Noordsy DL, Brunette MF et al (2008) Substance abuse and schizophrenia: pharmacotherapeutic intervention. J Subst Abuse Treat 34(1):61–71PubMedGoogle Scholar
  49. 49.
    Green MD, Renner JA (2009) Buprenorphine for the management of opioid dependence, Feature article. Essential Psychopharmacol 7(3):73–87Google Scholar
  50. 50.
    Gutstein HB, Akil H. (2001) Opioid analgesics. In: Hardman JG, Limbird LL (eds) Goodman and Gilman’s the pharmacologic basis of therapeutics. McGraw-Hill, New YorkGoogle Scholar
  51. 51.
    Hamilton SP, Nunes EV, Janal M et al (2000) The effect of sertraline on methadone plasma levels in methadone-maintained patients. Am J Addict 9(1):63–69PubMedGoogle Scholar
  52. 52.
    Handelsman L, Cochrane KJ, Aronson MJ et al (1987) Two new rating scales for opiate withdrawal. Am J Alcohol Abuse 13:293–308Google Scholar
  53. 53.
    Hasin DS, Hatzenbueler M, Smith S et al (2005) Co-occurring DSM-IV drug abuse in DSM-IV drug dependence: results from the national epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend 80(1):117–123PubMedGoogle Scholar
  54. 54.
    Hawkinson JE, Acosta-Burruel M, Espita SA (2000) Opioid activity profiles indicate similarities between the nociceptin/orphanin FQ and opioid receptors. Eur J Pharmacol 389(2–2):107–14PubMedGoogle Scholar
  55. 55.
    Higgins ST, Silverman K (2008) Contingency management. In:Galanter M, Kleber HD (eds) Textbook of substance abuse treatment, 4th edn. American Psychiatric Publishing, Washington, DCGoogle Scholar
  56. 56.
    Hiller ML, Knight K, Simpson DD (1999) Prison-based substance abuse treatment, residential aftercare and recidivism. Addiction 94(6):833–842PubMedGoogle Scholar
  57. 57.
    Huang B, Dawson DA, Stinson FS et al (2006) Prevalence, correlates, and comorbidty of nonmedical prescription drug use and drug use disorders in the United States: results of the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 67:1062–1073PubMedGoogle Scholar
  58. 58.
    Johnson LD, O'Malley PM, Bachman JG et al (2005) Monitoring the future: national survey results on drug use; 1975–2004. National Institute on Drug Abuse, Bethesda, MDGoogle Scholar
  59. 59.
    Johnson RE, Chutuape MA, Strain EC et al (2000) A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Eng J Med 343:1290–1297Google Scholar
  60. 60.
    Joranson DE, Ryan KM, Gilson AM et al (2000) Trends in medical use and abuse of opioid analgesics. JAMA 283:1710–1714PubMedGoogle Scholar
  61. 61.
    Kakko J, Svanborg KD, Kreek MJ et al (2003) 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomized, placebo-controlled trial. The Lancet 361(9358):662–668Google Scholar
  62. 62.
    Katz EC, Chutuape MA, Jones HE et al (2002) Voucher reinforcement for heroin and cocaine abstinence in an outpatient drug-free program. Drug Alcohol Depend 10(2):136–143Google Scholar
  63. 63.
    Kaye AD, Gervitz C, Bosscher HA et al (2003) Ultrarapid opiate detoxification: a review. Can J Anaesth 50:663–671PubMedGoogle Scholar
  64. 64.
    Keiffer BL, Befort K, Gaveriaux-Ruff C et al (1992) The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA 89:12048–12052; (1994) erratum in Proc Natl Acad Sci USA 91:1193Google Scholar
  65. 65.
    Kessler RC (1995) Epidemiology of psychiatric comorbidity. In: Tsuang MT, Tohen M, Zahner GEP (eds) Textbook in psychiatric epidemiology. Wiley, New YorkGoogle Scholar
  66. 66.
    Kessler RC (2004) The epidemiology of dual diagnosis: impact of substance abuse on the diagnosis, course, and treatment of mood disorders. Biol Psychiatry 56:730–737PubMedGoogle Scholar
  67. 67.
    Kessler RC, McGonagle KA, Zhao S et al (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the national comorbidity survey. Arch Gen Psychiatry 51:8–19PubMedGoogle Scholar
  68. 68.
    Kessler RC, Nelson CB, McGonagle KA et al (1996) The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 66:17–31PubMedGoogle Scholar
  69. 69.
    Kintz P (2002) A new series of 13 buprenorphine-related deaths. Clin Biochem 35:513–516PubMedGoogle Scholar
  70. 70.
    Kling MA, Carson RE, Borg L et al (2000) Opioid receptor imaging with PET and [(18)F] cyclofoxy in long-term methadone-treated former heroin addicts. J Pharmacol Exp Ther 295:1070–1076PubMedGoogle Scholar
  71. 71.
    Kosten TR, Kleber HD (1988) Buprenorphine detoxification from opioid dependence: a pilot study. Life Sci 42:635–671PubMedGoogle Scholar
  72. 72.
    Kosten TR, O’Connor PG (2003) Management of drug and alcohol withdrawal. N Engl J Med 348:1786–1795PubMedGoogle Scholar
  73. 73.
    Kosten TR, Morgan C, Kreek MJ (1992) Beta endorphine levels during heroin, methadone, buprenorphine, and naloxone challenges: preliminary findings. Biol Psychiatry 32:523–528PubMedGoogle Scholar
  74. 74.
    Kosten T, Falcioni, Oliveto A, Feingold A (2004) Depression predicts higher rates of heroin use on desipramine with buprenorphine than with methadone. Am J Addict 13:191–201PubMedGoogle Scholar
  75. 75.
    Kreek MJ (2008) Neurobiology of opiates and opioids. In: Galanter M, Kleber HD (eds) Textbook of substance abuse treatment, 4th edn. American Psychiatric Publishing, Washington, DCGoogle Scholar
  76. 76.
    Kreek MJ, Wardlaw SL, Hartman N et al (1983) Circadian rhythms and levels of beta-endorphin, ACTH, and cortisol during chronic methadone maintenance treatment in humans. Life Sci 33(Suppl 1):409–411PubMedGoogle Scholar
  77. 77.
    Kreek MJ, Ragunath J, Plevy S et al (1984) ACTH, cortical and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides 5:277–278PubMedGoogle Scholar
  78. 78.
    Kreek MJ, Schluger J, Borg L et al (1999) Dynorphin A1–13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulations of dopaminergic tone in the treatment of addictions. J Pharmacol Exp Ther 288:260–269PubMedGoogle Scholar
  79. 79.
    Kumar P, Jain MK (2003) Gabapentin in the management of pentazocine dependence: a potent analgesic-anticraving agent. J Assoc Physicians India 51:673–676PubMedGoogle Scholar
  80. 80.
    Linehan MM, Dimeff LA, Reynolds SK et al (2002) Dialectal behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid dependent women meeting criteria for borderline personality disorder. Drug Alcohol Depend 67:13–26PubMedGoogle Scholar
  81. 81.
    Ling W, Charuvastra C, Collins JF et al (1998) Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 93:475–486PubMedGoogle Scholar
  82. 82.
    Ling W, Amass L, Shoptaw S et al (2005) A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the national institute on drug abuse clinical trials network. Addiction 100(8):1090–1100PubMedGoogle Scholar
  83. 83.
    Lussier JP, Heil SH, Mongeon JA et al (2006) A meta-analysis of voucher-based reinforcement therapy for substance use disorders. Addiction 101(2):192–203PubMedGoogle Scholar
  84. 84.
    MacKenzie DL (2006) What works in corrections: reduciing the criminal activities of offenders and delinquents. Cambridge University, New YorkGoogle Scholar
  85. 85.
    Madras B (2007) Screening, brief intervention, referral and treatment (SBIRT) abstract #164901, American Public Health Association 135th Annual Meeting, Washington, DC, Nov 5, 2007Google Scholar
  86. 86.
    Margolin A, Kantak K, Copenhaver M, et al (2003) A preliminary, controlled investigation of magnesium L-aspartate hydrochloride for illicit cocaine and opiate use in methadone-maintained patients. J Addict Dis 22(2):49–61PubMedGoogle Scholar
  87. 87.
    Marissen MAE, Franken IH, Blanken P et al (2007) Cue exposure therapy for the treatment of opiate addiction: results of a randomized controlled clinical trial. Psychother Psychosom 76:97–105PubMedGoogle Scholar
  88. 88.
    McLellan AT, Hagan TA, Meyers K et al (1997) “Intensive” outpatient substance abuse treatment: comparisons with “traditional” outpatient treatment. J Addict Dis 16(2):57–84PubMedGoogle Scholar
  89. 89.
    McRae AL, Sonne SC, Brady KT et al (2004) A randomized, placebo-controlled trial of buspirone for the treatment of anxiety in opioid-dependent individuals. Am J Addict 13:53–63PubMedGoogle Scholar
  90. 90.
    Medina JL, Diamond S (1997) Drug dependency in patients with chronic headaches. Headache 17(1):12–14Google Scholar
  91. 91.
    Meier B (2003) Pain killer. Rodale, St. Martin’s, New YorkGoogle Scholar
  92. 92.
    Miller WR, Rollnick S (2002) Motivational interviewing: preparing people for change, 2nd edn. Guilford, New YorkGoogle Scholar
  93. 93.
    Mintzer IL, Eisenberg M, Terra M et al (2007) Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 5(2):146–150PubMedGoogle Scholar
  94. 94.
    Mitchell O, MacKenzie DL, Wilson DB (2006) The effectiveness of incarceration-based drug treatment on criminal behavior. Paper approved by the campbell collaboration, criminal justice review group. http://www.campbellcollaboration.org/doc-pdf/Incarceration-BasedDrugTxSept06final.pdf. Accessed 31 May 2010
  95. 95.
    Mollereau C, Parmentier M, Mailleux P et al (1994) ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 341(1):33–38PubMedGoogle Scholar
  96. 96.
    Monga N, Rehm J, Fischer B et al (2007) Using latent class analysis (LCA) to analyze patterns of drug use in a population of illegal drug abusers. Drug Alcohol Depend 88:1–8PubMedGoogle Scholar
  97. 97.
    Montoya ID, Schroeder JR, Preston KL et al (2005) Influence of psychotherapy attendance on buprenorphine treatment outcome. J Subst Abuse Treat 28(3):247–254PubMedGoogle Scholar
  98. 98.
    Najavits LK (2002) Seeking safety: a treatment manual for PTSD and substance abuse. Guilford, New YorkGoogle Scholar
  99. 99.
    National Institutes of Health, National Institute of Alcohol Abuse and Alcoholism (2005) Helping patients who drink too much: a clinician’s guide, updated 2005 ednGoogle Scholar
  100. 100.
    Neff JA, Moody DE (2001) Differential N-demethylation of L-a-acetylmethadol (LAAM) and norLAAM by cytochrome P450 s 2B6, 2C18, and 3A4. Biochem Biophys Res Commun 284:751–756PubMedGoogle Scholar
  101. 101.
    Nowinski J, Baker S, Carroll K (1992) NIAAA project MATCH Monograph series, vol 1. Twelve-step facilitation therapy manual: a clinical research guide for therapists treating individuals with alcohol abuse and dependence. Government Printing Office, Washington, DCGoogle Scholar
  102. 102.
    Nunes EV, Sullivan MA, Levin FR (2004) Treatment of depression in patients with opiate dependence. Biol Psychiatry 56:793–802PubMedGoogle Scholar
  103. 103.
    Nunes EV, Quitkin FM, Donovan SJ et al (1998) Imipramine treatment of opiate-dependent patients with depressive disorders: a placebo-controlled trial. Arch Gen Psychiatry 55:153–160PubMedGoogle Scholar
  104. 104.
    Obadia Y, Perrin V, Feroni I et al (2001) Injecting misuse of buprenorphine among French drug users. Addiction 96:267–272PubMedGoogle Scholar
  105. 105.
    O’Brien C, Greenstein RA, Mintz J et al (1975) Clinical experience with naltrexone. Am J Drug Alcohol Abuse 2:365–377PubMedGoogle Scholar
  106. 106.
    O’Connor PG, Kosten TR (1998) Rapid and ultra-rapid opioid detoxification techniques. JAMA 297(3):229–234Google Scholar
  107. 107.
    O’Connor PG, Waugh ME, Carroll KM, et al (1995) Primary care-based ambulatory opioid detoxification: the results of a clinical trial. J Gen Intern Med 10:255–260PubMedGoogle Scholar
  108. 108.
    O’Farrell TJ, Fals-Stewart W (2006). Behavioral couples therapy for alcoholism and drug abuse. Guilford, New YorkGoogle Scholar
  109. 109.
    O’Farrell TJ, Fals-Stewart W (2008) Family therapy. In: Galanter M, Kleber HD (eds) Textbook of substance abuse treatment, 4th edn. American Psychiatric Publishing, Washington, DCGoogle Scholar
  110. 110.
    Orsini MJ, Nesmelovai I, Young HC et al (2005) The nociceptin pharmacophore site for opioid receptor binding derived from the NMR structure and bioactivity relationships. J Biol Chem 280(9):8134–8142PubMedGoogle Scholar
  111. 111.
    Osser DN, Renner JA, Bayog R (2006) Algorithm for the pharmacotherapy of anxiety in chemical abusers. Psychopharmacology algorithm project, Harvard medical school. http://mhc.com/algorithms/ver4/startAnx.html. Accessed 24 July 2008
  112. 112.
    Pasternak GW (1987) Opioid receptos. In: Meltzer H (ed) Psychopharmacology: the third generation of progress. Raven, New YorkGoogle Scholar
  113. 113.
    Paulozzi LJ, Ryan GW (2006) Opioid analgesics and rates of fatal drug poisoning in the United States. Am J Prev Med 31:506–511PubMedGoogle Scholar
  114. 114.
    Pearson F, Lipton D (1999. A meta-analytic review of the effectiveness of corrections-based treatments for drug abuse. Prison J 79:384–410Google Scholar
  115. 115.
    Perry S, Heidrich G (1982) Management of pain during debridement: a survey of U.S. burn units. Pain 13(3):267–280PubMedGoogle Scholar
  116. 116.
    Petrakis I, Carrol KM, Nick C et al (1998) Fluoxetine treatment of depressive disorders iin methadone-maintained opioid addicts. Drug Alcohol Depend 50:221–226PubMedGoogle Scholar
  117. 117.
    Polydorou S, Kleber HD (2008) Detoxification of opioids. In: Galanter M, Kleber HD (eds) Textbook of substance abuse treatment, 4th edn. American Psychiatric Publishing, Washington, DCGoogle Scholar
  118. 118.
    Portenoy RK, Foley KM (1986) Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain 25(2):171–186PubMedGoogle Scholar
  119. 119.
    Porter J, Jick H (1980) Addiction rare in patients treated with narcotics. N Eng J Med 302(2):123Google Scholar
  120. 120.
    Posternak MA, Mueller TI (2001) Assessing the risks and benefits of benzodiazepines for anxiety disorders in patients with a history of substance abuse or dependence. Am J Addict 10(1):48–68PubMedGoogle Scholar
  121. 121.
    Raehal KM, Bohn LM (2005) Mu opioid receptor regulation and opioid responsiveness. AAPS J 7:E587–E591PubMedGoogle Scholar
  122. 122.
    Rawson RA, McCann MJ, Shoptaw SJ et al (2001) Naltrexone for opioid dependence: evaluation of a manualized psychosocial protocol to enhance treatment response. Drug Alcohol Res 20:67–78Google Scholar
  123. 123.
    Regier DA, Farmer ME, Rae DS et al (1990) Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) study. JAMA 264(19):2511–2518PubMedGoogle Scholar
  124. 124.
    Renner JA (2004) How to train residents to identify and treat dual diagnosis. Biol Psychiatry 56(10):810–816PubMedGoogle Scholar
  125. 125.
    Renner JA, Baxter JD, Suzuki J et al (2007) Substance abuse and depression. In: Ciraulo DA, Shader RI (eds) Pharmacology of depression, 2nd edn. Humana, Totowa, NJGoogle Scholar
  126. 126.
    Ries RK, Galante, M, Tonigan JS (2008) Twelve-step facilitation. In: Galanter M, Kleber HD (eds) Textbook of substance abuse treatment, 4th edn. American Psychiatric Publishing, Washington, DCGoogle Scholar
  127. 127.
    Riordan CE, Kleber HD (1980) Rapid opiate detoxification with clonidine and naloxone (letter). Lancet 1:1079–1080PubMedGoogle Scholar
  128. 128.
    Ritvo JI, Causey HL (2008) Community-based treatment. In: Galanter M, Kleber HD (eds) Textbook of substance abuse treatment, 4th edn. American Psychiatric Publishing, Washington, DCGoogle Scholar
  129. 129.
    Robles E, Stitzer MI, Strain EC et al (2002) Voucher-based reinforcement of opiate abstinence during methadone detoxification. Drug Alcohol Depend 65(92):179–189PubMedGoogle Scholar
  130. 130.
    Rosen D, Smith ML, Reynolds CF (2008) The prevalence of mental and physical health disorders among older methadone maintenance patients. Am J Geriatric Psychiatry 16(6):488–497Google Scholar
  131. 131.
    Roth A, Hogan I, Farren C et al (1997) Naltrexone plus group therapy for the treatment of opiate-abusing health-care professionals. J Subst Abuse Treat 14:19–22PubMedGoogle Scholar
  132. 132.
    Rounsaville BJ, Weissman MM, Kleber HD et al (1982) Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry 39:161–168PubMedGoogle Scholar
  133. 133.
    Saunders B, Wilkinson C, Phillips M (1995) The impact of a brief motivational intervention with opiate users attending a methadone program. Addiction 90(3):415–424PubMedGoogle Scholar
  134. 134.
    Scherbaum N, Kluwig J, Spicka M et al (2005) Group psychotherapy for opiate addicts in methadone maintenance treatment – a controlled trial. Eur Addict Res 11(4):163–171PubMedGoogle Scholar
  135. 135.
    Schluger JH, Bart G, Green M et al (2003) Corticotropin-releasing factor testing reveals a dose-dependent difference in methadone maintained vs. control subjects. Neuropsychopharmacology 28(5):985–994PubMedGoogle Scholar
  136. 136.
    Shader RI, Renner JA (2007) Opioid abuse and dependence: acute and chronic treatment. In Shader R (ed) Manual of psychiatric therapeutics, 4th edn. Lippincott Williams & Wilkins, Baltimore, MDGoogle Scholar
  137. 137.
    Sigmon SC (2006) Characterizing the emerging population of prescription opioid abusers. Am J Addict 15:208–212PubMedGoogle Scholar
  138. 138.
    Singh J, Basu D (2004) Ultra-rapid opioid detoxification: current status and controversies. J Postgrad Med 50:227–232PubMedGoogle Scholar
  139. 139.
    Smith LA, Gates S, Foxcroft D (2006) Therapeutic communities for substance related disorder. Cochrane Database Syst Rev 1:CD005338PubMedGoogle Scholar
  140. 140.
    Stitzer ML, Iguchi MY, Kidorf M et al (1993) Contingency management in methadone treatment: the case for positive incentives. NIDA Res Monogr 137:19–36PubMedGoogle Scholar
  141. 141.
    Strain EC, Stitzer ML, Liebson IA, et al. (1994) Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 151:1025–1030PubMedGoogle Scholar
  142. 142.
    Strain EC, Bigelow GE, Liebson IA et al. (1999). Moderate- vs. high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 281:1000–1005PubMedGoogle Scholar
  143. 143.
    Substance Abuse and Mental Health Services Administration. Office of Applied Studies (2005) Results from the 2004 national survey on drug use and health: national findings. Department of Health and Human Services, NSDUH Series H-28, DHHS publication SAM 05–4062, Rockville, MDGoogle Scholar
  144. 144.
    Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment (2007). 2007 SAMHSA evaluation of the impact of the DATA waiver program. http://hhtp://www.buprenorphine.samhsa.gov/evaluation.html. Accessed 4 Aug 2008
  145. 145.
    Tiet QQ, Mausbach B (2007) Treatments for patients with dual diagnosis: a review. Alcohol Clin Exp Res 31(4):513–536PubMedGoogle Scholar
  146. 146.
    United States Government Accountability Office (2007). Adult drug courts: evidence indicates recidivism reductions and mixed results for other outcomes (GAO-05–219). Washington, DC; US GAOGoogle Scholar
  147. 147.
    Villagomez RE, Meyer TJ, Lin MM et al (1995) Post-traumatic stress disorder among inner city methadone maintenance patients. Subst Abuse Treat 12:253–257Google Scholar
  148. 148.
    Volkow ND (2004) Imaging the addicted brain: from molecules to behavior. J Nucl Med 45:13 N–22 NGoogle Scholar
  149. 149.
    Volkow ND, Fowler JS, Wang GJ (2003) The addicted human brain: insights from imaging studies. J Clin Invest 111:1444–1451PubMedGoogle Scholar
  150. 150.
    Wallace AE, Weeks WB (2004) Substance abuse intensive outpatient treatment: does program graduation matter? J Subst Abuse Treat 27(1):27–30PubMedGoogle Scholar
  151. 151.
    Welsh C, Sherman SG, Tobin KE (2008) A case of heroin overdose reversed by sublingually administered buprenorphine/naloxone (Suboxone). Addiction 103(7):1226–1228PubMedGoogle Scholar
  152. 152.
    Wesson D, Ling W (2003) The clinical opiate withdrawal scale (COWS). Psychoactive Drugs 35(2):253–259Google Scholar
  153. 153.
    Wexler HK (1995) The success of therapeutic communities for substance abusers in American prisons. J Psychoactive Drugs 27(1):57–66PubMedGoogle Scholar
  154. 154.
    Woody GE, Luborsky L, McLellan AT et al (1983) Psychotherapy for opiate addicts. Does it help? Arch Gen Psychiatry 40(6):639–645PubMedGoogle Scholar
  155. 155.
    Woody GE, McLellan AT, Luborsky L et al (1995) Psychotherapy in community methadone programs: a validation study. Am J Psychiatry 152(9):1302–1308PubMedGoogle Scholar
  156. 156.
    Yablonski L (1965) The tunnel back. Macmillan, New YorkGoogle Scholar
  157. 157.
    Zullino DF, Cottier A, Besson J (2002) Case report: topiramate in opiate withdrawal. Prog Neuro-Psychopharmacol Biol Psychiatry 26(6):1221–12123Google Scholar
  158. 158.
    Zullino DF, Krenz S, Zimmerman G et al (2004) topiranate in opiate withdrawal – comparison with clonidine and with carbamazepine/mianserin. Subst Abuse 25(4):27–33Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Veterans Administration Outpatient ClinicBoston University School of MedicineBostonUSA
  2. 2.Department of PsychiatryBrigham and Women’s HospitalBostonUSA
  3. 3.Department of PsychiatryHarvard Medical SchoolBostonUSA

Personalised recommendations